Theravance Biopharma, Inc. 8-K

What Happened
Theravance Biopharma, Inc. filed a Current Report on Form 8‑K dated January 12, 2026, furnishing a corporate slide presentation (Exhibit 99.1) under Regulation FD. Members of management will hold one‑on‑one meetings with analysts and investors in San Francisco, CA, from January 12–15, 2026. The company states the information is being furnished (not "filed") and is not subject to Section 18 liability or to be incorporated by reference into registration statements except as expressly referenced.

Key Details

• Slide deck titled "Corporate Presentation – January 2026" furnished as Exhibit 99.1 to the Form 8‑K.
• Management meetings with analysts and investors scheduled for January 12–15, 2026 in San Francisco, CA.
• The information is furnished under Regulation FD and explicitly noted as not being "filed" for purposes of Section 18 of the Exchange Act.
• Form 8‑K was furnished on January 12, 2026.

Why It Matters
This filing signals that Theravance’s management is engaging directly with investors and that a formal presentation is available for review. Because the presentation was furnished under Regulation FD (not filed), it provides investor access to management's materials but does not carry the same legal status as a filed disclosure. Investors should review Exhibit 99.1 for any material business updates or data presented during the meetings.